SEC Form 4 · accession 0001562180-19-000860
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — CSO
Period of report
Feb 7, 2019
Accepted (ET)
Feb 8, 2019 · 6:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 7, 2019 | M | 82,500 | $3.00 | A | 224,988 | D | |
| Common Stock | Feb 7, 2019 | M | 104,764 | $4.20 | A | 329,752 | D | |
| Common StockF2 | Feb 7, 2019 | S | 187,264 | $21.5832 | D | 142,488 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $4.20 | Feb 7, 2019 | M | 104,764 | D | — | May 30, 2024 | Common Stock | 104,764 | 0 | D |
| Stock Option (Right to Buy)F4 | $3.00 | Feb 7, 2019 | M | 82,500 | D | — | Apr 1, 2026 | Common Stock | 82,500 | 82,500 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $21.50 to $21.785. Details of actual prices for shares sold are available from the Issuer upon request.
- F3The option vests in four equal annual installments beginning May 30, 2015.
- F4The option vests in four equal annual installments beginning on April 1, 2017.